These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10048148)

  • 1. Preclinical safety evaluation of human gene therapy products.
    Verdier F; Descotes J
    Toxicol Sci; 1999 Jan; 47(1):9-15. PubMed ID: 10048148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical development strategies for novel gene therapeutic products.
    Pilaro AM; Serabian MA
    Toxicol Pathol; 1999; 27(1):4-7. PubMed ID: 10367665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of gene transfer products: safety and immunological aspects.
    Christ M
    Toxicology; 2002 May; 174(1):13-9. PubMed ID: 11972987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PCR assay in the preclinical safety evaluation of nucleic acid medicines.
    Haworth R; Pilling AM
    Hum Exp Toxicol; 2000 May; 19(5):267-76. PubMed ID: 10918521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gene therapy: new developments].
    Mohr L; Geissler M
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2227-35. PubMed ID: 12564039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical safety evaluation of recombinant adeno-associated virus 2 vector encoding human tumor necrosis factor receptor-immunoglobulin Fc fusion gene.
    Zhou X; Shen L; Liu L; Wang C; Qi W; Zhao A; Wu X; Li B
    Hum Vaccin Immunother; 2016 Mar; 12(3):732-9. PubMed ID: 26837862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of a gene therapy clinical trial. From bench to bedside and back.
    Aguilar LK; Aguilar-Cordova E
    J Neurooncol; 2003 Dec; 65(3):307-15. PubMed ID: 14682380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral vectors: a look back and ahead on gene transfer technology.
    Vannucci L; Lai M; Chiuppesi F; Ceccherini-Nelli L; Pistello M
    New Microbiol; 2013 Jan; 36(1):1-22. PubMed ID: 23435812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral Vectors: The Road to Reducing Genotoxicity.
    David RM; Doherty AT
    Toxicol Sci; 2017 Feb; 155(2):315-325. PubMed ID: 27803388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not reinventing the wheel: applying the 3Rs concepts to viral vector gene therapy biodistribution studies.
    MacLachlan TK; McIntyre M; Mitrophanous K; Miskin J; Jolly DJ; Cavagnaro JA
    Hum Gene Ther Clin Dev; 2013 Mar; 24(1):1-4. PubMed ID: 23692377
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety assessment of biotechnology-derived pharmaceuticals: ICH and beyond.
    Serabian MA; Pilaro AM
    Toxicol Pathol; 1999; 27(1):27-31. PubMed ID: 10367669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues.
    Smith KT; Shepherd AJ; Boyd JE; Lees GM
    Gene Ther; 1996 Mar; 3(3):190-200. PubMed ID: 8646549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quality control of gene therapy products: approach of the French Agency for the Safety of Health Products].
    Chenivesse X; Ridoux V; Tissier MH
    Med Sci (Paris); 2003 Apr; 19(4):481-8. PubMed ID: 12836223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving gene therapy approaches for osteosarcoma using viral vectors: review.
    Witlox MA; Lamfers ML; Wuisman PI; Curiel DT; Siegal GP
    Bone; 2007 Apr; 40(4):797-812. PubMed ID: 17189720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy.
    Sugimoto M; Watanabe M; Kaku H; Li SA; Noguchi H; Ueki H; Sakaguchi M; Huh NH; Nasu Y; Kumon H
    Oncol Rep; 2012 Nov; 28(5):1645-52. PubMed ID: 22941469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-focusing therapeutic gene delivery with intelligent gene vector swarms: intra-swarm signalling through receptor transgene expression in targeted cells.
    Tolmachov OE
    Artif Intell Med; 2015 Jan; 63(1):1-6. PubMed ID: 25547266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Issues with biotechnology products in toxicologic pathology.
    Terrell TG; Green JD
    Toxicol Pathol; 1994; 22(2):187-93. PubMed ID: 7973366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector.
    O'Neal WK; Zhou H; Morral N; Langston C; Parks RJ; Graham FL; Kochanek S; Beaudet AL
    Mol Med; 2000 Mar; 6(3):179-95. PubMed ID: 10965494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical study of rAAV2-sTRAIL: pharmaceutical efficacy, biodistribution and safety in animals.
    Ru Q; Li W; Wang X; Zhang S; Chen L; Zhang Y; Ge Y; Zu Y; Liu Y; Zheng D
    Cancer Gene Ther; 2017 Jun; 24(6):251-258. PubMed ID: 28429751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.